Metabolic monitoring in commercially insured pediatric patients newly initiated to take a second-generation antipsychotic

JAMA Pediatr. 2014 Jul;168(7):679-81. doi: 10.1001/jamapediatrics.2014.224.

Authors

Thomas Delate¹, Yardlee S Kauffman¹, Sheila R Botts², Charlyn Wong³, Kerri M Gaughan²

Affiliations

¹ Kaiser Permanente Colorado, Aurora2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora.
² Department of Behavioral Health, Kaiser Permanente Colorado, Aurora.
³ Kaiser Permanente Northern California, Oakland.

PMID: 24796974
DOI: 10.1001/jamapediatrics.2014.224

No abstract available

MeSH terms

Adolescent
Antipsychotic Agents / adverse effects
Antipsychotic Agents / therapeutic use*
Biomarkers / analysis
Child
Child Health Services / statistics & numerical data*
Child, Preschool
Drug Monitoring / statistics & numerical data
Female
Humans
Infant
Infant, Newborn
Insurance, Health
Male
Mental Disorders / drug therapy*
Mental Disorders / metabolism
Monitoring, Physiologic / statistics & numerical data*
Pediatrics / statistics & numerical data*
Retrospective Studies
Treatment Outcome

Substances

Antipsychotic Agents
Biomarkers